Octreotide therapy for hepatocellular carcinoma: A systematic review of the evidence from randomized controlled trials

Hepato-Gastroenterology

Volumn 57, Issue 98, 2010, Pages 292-299

  Jia, Wei Dong ^a   Zhang, Chuan Hai ^a   Xu, Ge Liang ^a   Ge, Yong Sheng ^a   Wang, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Octreotide; Survival

Indexed keywords

OCTREOTIDE;

ARTICLE; CANCER THERAPY; DRUG EFFECT; DRUG FORMULATION; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; OCTREOTIDE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 77954122054     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. Murray CJL, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
3. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
5. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
6. Itamoto T, Nakahara H, Tashiro H, et al: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80: 143-8.
7. Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83
8. Chow PK, Tai BC, Tan CK, et al: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36: 1221-6.
9. Gallo C, Daniele B, Gaeta GB: Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998; 352:17-20.
10. Lai CL, Lau JY, Wu PC, et al: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389-94.
11. Llovet JM, Sala M, Castells L, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 64-8.
12. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
13. Kouroumalis E, Skordilis P, Thermos K, et al: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442-7.
14. Yuen MF, Poon RT, Lai CL, et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 687-91.
15. Becker G, Allgaier HP, Olschewski M, et al: Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
16. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al: Long-acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors. A randomized placebo controlled trial. World J Gastroenterol 2007; 13: 3164-3170.
17. Johnson P, Bruix J: Hepatocellular carcinoma and the art of prognostication. J Hepatol 2000; 33: 1006-1008.
18. Samonakis DN, Notas G, Christodoulakis N, et al: Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 2008; 53: 2359-2365.
19. Slijkhuis WA, Stadheim L, Hassoun ZM, et al: Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005; 39: 333-338.
20. Reubi JC, Kvols L, Krenning E, et al: Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39: 78-81.
21. Patel YC, Srikant CB et al: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994; 135: 2814-2817.
22. Ferjoux G, Bousquet C, Cordelier P, et al: Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000; 94: 205-210.
23. Schally AV, Redding TW: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 1987; 84: 7275-7279.
24. Jia WD, Xu GL, Xu RN, et al: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003; 129: 327-334.
25. Corbetta S, Ballaré E, Mantovani G, et al: Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001; 31: 208-214.
26. Reubi JC, Zimmermann A, Jonas S, et al: Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45: 766-774. (Pubitemid 29492155)
27. Samonakis DN, Moschandreas J, Arnaoutis T, et al: Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002; 9: 903-907